Researchers have discovered a ‘handbrake’ mechanism controlling how cells respond to cancer drugs, which could reshape understanding of cancer drug resistance. 

The breakthrough research, led by scientists from the University of Oxford and the Research Centre for Molecular Medicine, Austria, demonstrates how the enzyme NUDT5 acts as a molecular ‘handbrake’ on the enzyme PPAT. 

PPAT controls the rate of purine synthesis and, without the NUDT5 ‘handbrake’, cells can overproduce purines. These purines can out-compete certain cancer drug treatments, making the treatments ineffective. However, when NUDT5 restrains PPAT, the cell’s nucleotide supply is fine-tuned, limiting DNA replication. 

The study may explain why some patients respond better than others to long-used drugs such as 6-thioguanine, used in leukaemia and autoimmune disease.  

“This discovery was a big surprise, in the best possible way,” said Professor Kilian Huber, who led the work from Oxford’s Centre for Medicines Discovery, part of the Nuffield Department of Medicine.  

“An enzyme long thought to have a single, well-defined role turned out to moonlight as a molecular scaffold, something never seen before in this enzyme family. It challenges the textbook view of how cells regulate the production of DNA building blocks and offers a fundamental insight into cellular control.  

 “Our team is now evaluating NUDT5-PPAT as a potential biomarker in clinical samples, advancing NUDT5 degraders through preclinical testing, and exploring whether other enzymes might have similar hidden scaffold roles in cell metabolism.”  

‘Unprecedented’ results could ‘pave the way for future discoveries’

Prior to the world-first discovery, published in Science, researchers at the University of Oxford had demonstrated that NUDT5 can be targeted by drug-like small molecules, opening the door to probe its biological roles in cells. 

In the latest study, the Oxford team developed dNUDT5, a first-in-class small-molecule degrader that removes NUDT5 entirely from cultured human cells. Unlike traditional enzyme blockers, this approach revealed that the protein also acts as a scaffold, tightly binding and inhibiting PPAT, the key enzyme required for purine production. Removing NUDT5 abolished the brake on purine synthesis and provided direct evidence of the mechanism.  

Using proteomics, the researchers then discovered that NUDT5 physically interacts with PPAT, explaining how this enzyme can control metabolism through structure rather than chemistry. Researchers also found that dNUDT5 could rescue adenosine-induced toxicity in patient-derived fibroblasts from individuals with MTHFD1 deficiency, showing the pathway’s broader biomedical relevance.  

“In this study we have shown an unprecedented role of NUDT5 in repressing the purine de novo biosynthetic pathway,” said Dr Anne-Sophie Marques, co-first author on the study.  

“In addition to proving that the scaffolding role of NUDT5 is essential in this phenotype, we have demonstrated that the interaction between NUDT5 and PPAT, the rate-limiting enzyme of purine de novo synthesis, acts like a switch to repress the pathway.  

 “It is undeniable that our results pave the way for future discoveries around the NUDT5 protein and its role in cancer.”   

 

Bruno Quinney, Content Team, DDW